About Us
Leadership
Portfolio
News
01.25.23
ByHeart Acquires Additional Domestic Infant Formula Manufacturing Facility Tripling its Supply Capacity and Continuing to Fortify Formula Production in the U.S.
01.09.23
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
01.05.23
ByHeart to Acquire Packaging Company Cascadia Nutrition
12.11.22
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting
12.07.22
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial
11.29.22
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
11.28.22
AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy
11.10.22
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
10.31.22
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
10.11.22
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
10.05.22
IconOVir Bio to Present Preclinical Data on Lead Candidate ICVB-1042 at SITC 2022
09.23.22
Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit
09.22.22
The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies
09.14.22
Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering
09.12.22
Scorpion Therapeutics, Volastra Therapeutics and ReCode Therapeutics Selected in Fierce Biotech’s 2022 Fierce 15
08.22.22
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia
08.16.22
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML
08.11.22
Breakthrough Properties Enters the Boulder Market with Acquisition and Development of Boulder 38 by Breakthrough
08.09.22
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
08.04.22
Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results
08.03.22
Breakthrough Properties Commences Construction of One Canal by Breakthrough, a Premier Life Science Research Center Along East Cambridge Waterfront
07.12.22
Affini-T Therapeutics Appoints Jill DeSimone to its Board of Directors
07.12.22
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
06.29.22
Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate with a Best-in-Class Profile
06.23.22
IconOVir Bio Appoints William Kaelin, Jr., M.D., to Board of Directors
06.16.22
ByHeart Announces Published Data in a Scholarly Journal on Benefits of The Novel High Quality Protein Blend in Their Groundbreaking Next-Generation 'Easy to Digest' Infant Formula
06.10.22
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress
06.06.22
IconOVir Bio Appoints John Huynh, Ph.D., as Chief Technology Officer
06.02.22
Scorpion Therapeutics Announces Discovery Scientific Advisory Board
05.19.22
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
05.16.22
Breakthrough Properties Acquires Best-in-Class Life Sciences Development Site at 2300 Market in Philadelphia's Vibrant Center City District
05.10.22
Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors
05.03.22
Breakthrough Properties Acquires St. John's Innovation Park Building in Cambridge, UK's Premier Life Sciences and Technology Cluster
04.29.22
Arie and Dan Belldegrun are building biotech campuses around the globe — with a newly raised $3B fund to keep the dirt flying
04.29.22
Breakthrough Properties Raises $3 Billion to Develop Next Generation Life Science Ecosystems
04.28.22
ByHeart Celebrates the FDA Registration of their Reading, Pennsylvania Facility, Becoming the First New Infant Formula Manufacturer in the U.S. in Over 15 Years
04.27.22
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
04.14.22
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
04.13.22
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal
04.08.22
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data Supporting the Development of Its Potentially Best-in-Class Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors at the AACR Annual Meeting 2022
04.05.22
Affini-T Expands Board of Directors with Appointments of Michael Varney, Ph.D., and Daniel Faga
04.04.22
Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. To Its Board Of Directors
03.23.22
ByHeart Announces the Launch of its Groundbreaking Infant Formula, Becoming the Only New Infant Formula Brand in Decades to Rewrite the Recipe From Scratch
03.23.22
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
03.23.22
LabCentral Ignite Platform for Life Sciences Diversity Awarded $400,000 in Grants and Matching Funds from the U.S. Economic Development Administration's STEM Talent Challenge and Breakthrough Properties
03.22.22
Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations
03.14.22
Ginkgo Bioworks Signs Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform
03.10.22
Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
03.09.22
Breakthrough Properties Launches “STUDIOLABS BY BREAKTHROUGH” As Part Of Its Rapidly Expanding Life Science Real Estate Portfolio
03.01.22
Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report
03.01.22
Helen S. Kim Joins IGI’s HS Chau Women in Enterprising Science Program as an Entrepreneurial Advisor
02.23.22
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
02.01.22
Breakthrough Properties Acquires 1.7-Acre Site for Its First Ground-Up Life Sciences Development in the UK
01.11.22
Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer
01.11.22
Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
01.10.22
Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
01.06.22
Kyverna Therapeutics Announces Exclusive Worldwide Licenses With National Institutes of Health for Autologous and Allogeneic Anti-CD19 CAR T Cellular Therapies to Treat Autoimmune Diseases
12.15.21
Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
12.13.21
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
12.06.21
Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
11.29.21
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
11.22.21
Scorpion Therapeutics Announces Appointment of Brian Piper as Chief Financial Officer
11.22.21
BD Selects Torrey View by Breakthrough as San Diego Campus for Growing Biosciences Business
11.17.21
Protego Biopharma Raises $51 Million Series A Financing to Advance the Treatment of Protein Misfolding Diseases
10.28.21
ByHeart Has Become the First and Only Infant Formula in the US to Receive Clean Label Project Certification
10.26.21
Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs
10.21.21
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million
10.20.21
LianBio Announces Launch of Initial Public Offering
09.14.21
Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds
09.09.21
Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis
08.18.21
Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases
08.12.21
Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
08.02.21
Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
07.26.21
ByHeart Secures $90M Series B Financing and Achieves All of its Clinical Trial Endpoints
07.07.21
Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D.
06.24.21
Vida Ventures Closes $825 Million Vida III Fund to Advance Transformative Biomedical Innovations
06.21.21
Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer
06.21.21
Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
06.04.21
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06.04.21
Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
06.02.21
ByHeart Completes Largest US Clinical Trial for a New Infant Formula Brand in the Last 25 Years Supporting their Innovation in Baby Nutrition
06.01.21
LA 500 Most Influential People 2021
05.28.21
Centessa Announces Pricing of Initial Public Offering
05.20.21
IconOVir Bio Announces Preclinical Proof-of-Concept Data for Proprietary Mutations Designed to Improve Selectivity of Novel Oncolytic Viruses, Including Lead Product Candidate ICVB-1042
05.19.21
Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021
05.19.21
Legacies: 60 biopharma pioneers over 60 who helped birth a tech revolution in the making
05.11.21
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day
05.11.21
Ginkgo Bioworks to Become a Public Company and Expand its Leading Platform for Cell Programming
05.10.21
Centessa Pharmaceuticals Appoints One of the World’s Leading Drug Developers, Antoine Yver, M.D., M.Sc., as Chief Medical Officer
04.15.21
Tectonic Therapeutic Launches with $80 Million Series A Financing to Transform the Discovery of Novel G-Protein Coupled Receptor (GPCR)-Targeted Therapies
04.06.21
Volastra Therapeutics Extends Seed Financing to $44 Million to Advance Drug Discovery Programs to Prevent Cancer Metastasis
03.18.21
Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors
02.16.21
Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model
01.26.21
Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors
01.26.21
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine
01.13.21
UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
01.05.21
IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors
12.15.20
Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies
12.07.20
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
12.06.20
Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology
12.05.20
Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting
12.02.20
Kinnate Biopharma Announces Pricing of Initial Public Offering
11.20.20
Precision Medicine Group Secures Major Investment from Blackstone
11.19.20
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China
11.18.20
PIONYR Immunotherapeutics Initiates Phase 1 Clinical Study Of PY314
11.11.20
Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021
11.04.20
Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology
10.29.20
LianBio Announces $310 Million Crossover Financing
10.26.20
Scorpion Therapeutics Launches with $108 Million to Advance Precision Oncology 2.0
10.26.20
Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy
10.22.20
Kronos Bio Announces Publication of Preclinical Study Results for Investigational CDK9 Inhibitor KB-0742 in Cell Chemical Biology
10.20.20
Praxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
10.16.20
Pontifax Taps Larger LPs Hungry for Co-Investments for $302m Fund II Close
10.15.20
Praxis Precision Medicines Announces Pricing of Upsized Initial Public Offering
10.14.20
Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
10.08.20
Pontifax AgTech Closes Second Fund at $302 million - Wall Street Journal
10.06.20
Neogene Therapeutics Appoints Former Roche Chairman and Chief Executive Officer Franz B. Humer, Ph.D., as Executive Chairman of Board of Directors
10.06.20
A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics
09.14.20
Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies
08.26.20
Kinnate Biopharma Closes $98 Million Series C Financing
08.24.20
Kronos Bio Announces $155 Million Private Financing
08.19.20
Kronos Bio Appoints Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development
08.10.20
Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases
07.28.20
Praxis Precision Medicines Announces $110 Million Financing
07.28.20
Breakthrough Properties Executes Full-Building Lease With Leading Gene Editing Company for Next Generation Life Science Development in Boston's Seaport Neighborhood
07.20.20
Kronos Bio Appoints Barbara Kosacz, Chief Operating Officer and General Counsel
07.16.20
Kronos Bio and Gilead Sciences Enter Into Asset Purchase Agreement for Gilead’s SYK Inhibitor Portfolio
07.09.20
Kronos Bio Reports Positive Results of Preclinical Study of KB-0742, an Investigational CDK9 Inhibitor, Demonstrating Potency, Selectivity and Anti-tumor Activity in Prostate Cancer Model
07.07.20
Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board
07.07.20
Kronos Bio Appoints Industry Veteran, Jennifer Nicholson, M.H.A., as Vice President, Regulatory Affairs
07.01.20
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize
06.24.20
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
06.22.20
Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR™ at the American Association for Cancer Research (AACR) Virtual 2020 Meeting
06.22.20
Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia
06.15.20
Kronos Bio Expands Leadership Team with Appointment of Seasoned Drug Discovery Leader Christopher Dinsmore, Ph.D., as Chief Scientific Officer
06.01.20
Allogene Therapeutics Announces Commencement of Public Offering of Common Stock
06.01.20
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
05.29.20
Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
05.29.20
Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting
05.19.20
Kronos Bio Expands Clinical Team with the Appointment of Zung To as Vice President, Clinical Operations
05.15.20
UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer
05.15.20
UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto™ in Patients with Low-Grade Upper Tract Urothelial Cancer
05.13.20
American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma
05.07.20
UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments
05.06.20
Allogene Therapeutics Reports First Quarter 2020 Financial Results
05.04.20
Praxis Precision Medicines Launches with over $100 Million to Advance Pipeline of High Impact Therapies for Brain Disorders
04.29.20
Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
04.15.20
UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer
04.14.20
ByHeart Secures $70M Series A Financing Ahead of First Planned Product Launch in 2021
04.03.20
UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
04.01.20
Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
03.26.20
ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing
03.23.20
UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development
03.02.20
UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments
02.27.20
Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
01.13.20
Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
01.08.20
UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference
01.02.20
Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
12.19.19
Harvard taps Tishman Speyer to manage first phase of its new 36-acre research campus — and biotechs can't wait
12.19.19
Kinnate Biopharma Closes $74.5M Series B Financing
12.19.19
UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101
11.20.19
Kronos Bio Appoints Biopharma Industry Veteran Jorge F. DiMartino, M.D., Ph.D., as Chief Medical Officer
11.11.19
UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers
11.06.19
Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting ALLOCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting
11.05.19
Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications
10.24.19
Kronos Bio Strengthens Senior Management Team with New Leadership Appointments
10.08.19
Vida Ventures Appoints New Chief Financial and Operating Officer
09.24.19
UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances
09.24.19
UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer
09.19.19
Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
08.01.19
Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation
07.18.19
Kronos Bio Completes $105 Million Series A Financing
07.16.19
Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-of-Its-Kind Global Life Sciences Real Estate Platform
12.04.18
Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
11.28.18
Kronos Bio Appoints Philip Gutry as Chief Business Officer to Expand Pipeline Opportunities
10.15.18
Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
10.10.18
Allogene Therapeutics Announces Pricing of Initial Public Offering
10.02.18
FierceBiotech names Kronos Bio as one of its “Fierce 15” Biotech Companies of 2018
09.27.18
Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors
09.14.18
Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering
09.06.18
Allogene Therapeutics Completes a $120 Million Private Financing
08.28.18
Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality
08.14.18
Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer
07.11.18
Allogene Therapeutics Announces Scientific Advisory Board
06.18.18
Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer
06.05.18
UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance
06.04.18
Allogene Therapeutics Appoints Alison Moore, Ph.D. as Chief Technical Officer
05.30.18
Allogene Therapeutics Announces Board of Directors
05.23.18
Kronos Bio Appoints Dr. Norbert Bischofberger, Former Head of R&D for Gilead Sciences, as President and Chief Executive Officer and Completes $18 Million Seed Financing
05.21.18
UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
05.16.18
Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breakter at the International Investigative Dermatology Congress
05.15.18
Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
04.03.18
Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies
03.12.18
Sienna Biopharmaceuticals announces First Patient Dosed in Proof-Of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
02.22.18
Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer
02.22.18
New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
02.14.18
UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer
02.14.18
Sienna Biopharmaceuticals announces First Patient Dosed in First-In-Human Trial of Topical SNA-125
02.05.18
Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
01.30.18
Hubble Contacts Launches Subscription Service in the UK
01.23.18
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option
01.18.18
Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
01.16.18
Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
01.08.18
UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer
12.12.17
UroGen Pharma Expands Clinical Development Leadership Team
12.11.17
Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
12.10.17
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
12.07.17
Gilead Sciences and Kite to Acquire Cell Design Labs
11.29.17
Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
11.15.17
Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Investigational Cell Therapy
11.06.17
UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder
11.02.17
UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors
10.26.17
UroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs
10.24.17
Sienna Biopharmaceuticals announces First Patient Dosed In Phase 2B Trial of Topical SNA-120
10.18.17
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
10.06.17
Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy
10.04.17
Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress
10.03.17
Gilead Sciences Completes Acquisition of Kite Pharma, Inc.
09.06.17
UroGen Pharma Strengthens Management Team with the Appointment of Paul Chu as Vice President of Business Development
08.29.17
UroGen Pharma Receives FDA Fast Track Designation for MitoGel™ for the Treatment of Upper Tract Urothelial Carcinoma (UTUC)
08.28.17
Hubble Contacts Closes Series A-III Financing to Support Global Growth
08.28.17
Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
08.08.17
Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma
08.03.17
Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
08.01.17
Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
08.01.17
Cell Design Labs Appoints Roger Sidhu, M.D. As Chief Medical Officer
07.31.17
Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel
07.26.17
Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
07.20.17
Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute
07.19.17
Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan
07.18.17
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy
06.27.17
Kite Named to the MIT Technology Review’s Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy
06.14.17
Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors
06.07.17
Cell Design Labs Announces Issuance of Broad Patent for Chimeric Notch Receptor to Treat Cancer and other Diseases
06.05.17
Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia
05.26.17
Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel
05.16.17
UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors
05.10.17
UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option
05.08.17
Capricor Therapeutics Announces Private Placement of Common Stock
04.25.17
Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy
04.24.17
UroGen Pharma Welcomes New Board Member Kate Falberg
04.24.17
Sienna Biopharmaceuticals Announces $40 Million Series B Financing
04.06.17
Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards
04.03.17
UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma
04.02.17
Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting
03.31.17
New Gene Therapy for Cancer Offers Hope to Those With No Options Left
03.31.17
Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)
03.24.17
Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
03.20.17
Hubble Contacts Wants To Do For Contact Lenses What Harry’s Did For Razors
03.15.17
Cell Design Labs Announces Issuance of a Broad Patent for Programmable CAR-T Cells to Treat Cancer and Other Diseases
03.14.17
Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy
03.08.17
Kite Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
03.07.17
Hubble raises $16.5 million to deliver affordable daily contact lenses
02.28.17
Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma
02.28.17
Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals
02.09.17
Cell Design Labs’ Scientific Founder Co-Authors Review Article Illustrating Power and Potential of Engineered Human Cells to Treat Cancer
01.10.17
Kite Pharma and Fosun Pharma Establish Joint Venture in China to Develop and Commercialize Autologous T-Cell Therapies to Treat Cancer
01.09.17
Kite Pharma Establishes a Strategic Partnership With Daiichi Sankyo to Develop and Commercialize Axicabtagene Ciloleucel (KTE-C19) in Japan
01.03.17
Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6
12.12.16
Kite Pharma Announces Publication of T-Cell Therapy Targeting Mutant KRAS in Cancer by the National Cancer Institute (NCI) in New England Journal of Medicine
12.12.16
UroGen Pharma Announces FDA Acceptance of Investigational New Drug Application for MitoGel, a Novel Sustained Release Formulation of Mitomycin C, for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma
12.06.16
Sienna Biopharmaceuticals Acquires Creabilis plc
12.04.16
Kite Pharma Reports 82 Percent of Patients Achieved Complete Remission in Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia
12.04.16
Kite Pharma Initiates Rolling Submission of U.S. Biologics License Application (BLA) for KTE-C19, its Investigational anti-CD19 CAR-T Therapy, for the Treatment of Patients with Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)
11.10.16
Capricor Therapeutics Announces Plans to Expand Clinical Development Program in Duchenne Muscular Dystrophy to Evaluate Peripheral and Respiratory Muscle Function
11.01.16
Hubble Contacts raises $7.2 million to deliver disposable lenses direct to consumers
11.01.16
This startup wants to deliver affordable contact lenses straight to your door
10.31.16
Hubble Wants to Do for Contact Lenses What Warby Parker Did for Eyeglasses
10.31.16
Capricor Therapeutics Presents Positive 12-Month Results from DYNAMIC at TCT 2016
10.20.16
Capricor Therapeutics Awarded Up to $4.2 Million from National Institutes of Health to Evaluate Exosomes for Hypoplastic Left Heart Syndrome
10.19.16
Kite Pharma Details KTE-C19 Launch Preparedness and Near-Term, Next Generation CAR/TCR Product Candidates at Investor Day
10.14.16
UroGen Pharma Announces Agreement to License RTGel™ for Use with Neurotoxins to Allergan
10.06.16
Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)
09.29.16
CELL DESIGN LABS ANNOUNCES PEER-REVIEWED PUBLICATION VALIDATING ABILITY TO PROGRAM IMMUNE CELLS TO TREAT CANCER AND AUTOIMMUNE DISEASE
09.26.16
Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL)
09.26.16
Capricor Therapeutics Awarded $2.4 Million from U.S. Department of Defense to Support Manufacturing Process Development for Therapeutic Exosomes
09.21.16
Capricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds
09.20.16
Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS
08.16.16
Arno Completes $2.8 Million Private Placement
07.27.16
Kite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies
07.25.16
Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies
07.12.16
Sienna Biopharmaceuticals Announces Second Closing of Series A Financing
06.20.16
Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)
06.20.16
Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility
06.16.16
Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial
06.06.16
Kite Pharma Presents Ongoing Complete Responses at 9 Months in Phase 1 of ZUMA-1 in Patients with Chemorefractory Non-Hodgkin Lymphoma
06.06.16
Kite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)
06.06.16
Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions in Advanced Non-Hodgkin Lymphoma
06.02.16
Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies
06.02.16
Cell Design Labs Executes Series of Private Financings
05.05.16
UroGen Pharma Announces Three Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association’s 2016 Annual Meeting
05.02.16
Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications
04.28.16
Sienna Biopharmaceuticals Announces $34 Million Series A Financing
04.19.16
Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA
04.19.16
Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting
04.04.16
Capricor Therapeutics Announces DSMB Recommends Continuation of HOPE-Duchenne Clinical Trial
03.21.16
Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II
03.17.16
Kite Pharma Announces Clinical Collaboration to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma
03.17.16
Capricor Awarded $3.4 Million Grant from California Institute for Regenerative Medicine
03.16.16
Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research (AACR)
02.22.16
Capricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial
02.08.16
UroGen Pharma Strengthens Board of Directors and Senior Management Team
01.15.16
Capricor Therapeutics Announces $4 Million Registered Direct Offering
01.13.16
UroGen Pharma Strengthens Leadership Team and Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset
01.13.16
Arno Therapeutics Completes $7.4 Million Common Stock Financing
01.13.16
Kite Pharma and Leiden University Medical Center Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers
01.07.16
Kite Pharma Expands Its Clinical and Research Partnership With the National Cancer Institute (NCI) for Next-Generation CAR Programs to Treat B-Cell Malignancies
01.05.16
Capricor Therapeutics to Present at Biotech Showcase 2016
12.21.15
Kite Pharma Appoints Industry Leader Shawn Cline Tomasello as Chief Commercial Officer
12.10.15
Capricor Therapeutics to Present at the 2015 JMP Securities DMD Forum
12.08.15
Kite Pharma Announces Proposed Public Offering of Common Stock
12.07.15
Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for the Treatment of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)
12.07.15
Kite Pharma Initiates the ZUMA-4 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Children and Young Adults
12.07.15
Kite Pharma Presents Phase 1 Results From ZUMA-1 at the 57th American Society of Hematology (ASH) Annual Meeting
12.07.15
Kite Pharma Announces Clinical Biomarker Results of Anti-CD19 CAR T Cell Therapy at the 57th American Society of Hematology Annual Meeting (ASH)
12.03.15
Kite Pharma and GE Global Research Announce Strategic Collaboration to Automate Manufacturing of Engineered T Cell Therapies
12.02.15
Kite Pharma Initiates the ZUMA-3 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Adult Subjects
11.24.15
Capricor Therapeutics to Present at the 2015 Piper Jaffray Healthcare Conference
11.16.15
Arno Therapeutics Reports Third Quarter 2015 Financial Results and Business Update
11.12.15
Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update
11.12.15
Capricor Therapeutics Reports Third Quarter 2015 Business & Financial Highlights
11.09.15
Kite Pharma Initiates Phase 2 Clinical Study of KTE-C19 (ZUMA-2) in Patients With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) to Support Registration for a Second Indication
11.09.15
Capricor Therapeutics Presents Positive Data from the DYNAMIC Clinical Trial at 2015 American Heart Association Scientific Sessions
11.05.15
Capricor Therapeutics To Present Data from the DYNAMIC Clinical Trial at American Heart Association Scientific Sessions 2015
11.05.15
Kite Pharma to Present Four Abstracts, including Safety and Efficacy Data from the KTE-C19 Phase 1 Study in Patients with Refractory, Aggressive NHL (ZUMA-1), at the 57th American Society of Hematology Annual Meeting (ASH)
11.04.15
Capricor Therapeutics to Hold Third Quarter 2015 Business Update and Financial Results Conference Call on November 12, 2015 at 4:30 p.m. EST
11.04.15
Kite Pharma to Present at Upcoming Investor Conferences in November 2015
10.29.15
Capricor Therapeutics and CureDuchenne to Host Webinar on November 3, 2015 at 3:00 p.m. ET
10.27.15
Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment
10.27.15
Kite Pharma Initiates ZUMA-1 Phase 2 in Patients With Aggressive, Refractory Non-Hodgkin’s Lymphoma (NHL) to Support Registration of KTE-C19
10.21.15
Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains
10.15.15
Kite Pharma Receives Positive Opinions for Orphan Drug Designation in the European Union (EU) for KTE-C19 in Three Additional Hematological Indications
10.15.15
Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE
10.07.15
Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From the American Cancer Society
10.01.15
Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers
09.30.15
Capricor Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa
09.25.15
Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference
09.24.15
Arno Therapeutics’ AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients with Serious Bacterial Infections
09.19.15
Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
09.19.15
Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition
09.15.15
Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharma’s Board of Directors
09.14.15
Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)
09.14.15
AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
09.11.15
Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Cancer T-Cell Immunotherapy
09.03.15
Kite Pharma to Participate in Upcoming Investor Conferences in September 2015
09.03.15
Kite Pharma Commends Honors Conferred to Scientific Advisory Board Members for Their Significant Contributions to Medicine
09.01.15
Arno Therapeutics to Present at 17th Annual Rodman & Renshaw Conference
08.18.15
Arno Therapeutics Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer
08.17.15
Kite Pharma Provides Update on KTE-C19 Clinical Trial
08.14.15
Kite Pharma to Hold Conference Call to Provide a Corporate Update on Monday, August 17, 2015
08.14.15
Arno Therapeutics Reports Second Quarter 2015 Financial Results and Business Update
08.13.15
Capricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights
08.10.15
Kite Pharma Reports Second Quarter 2015 Financial Results
08.06.15
Kite Pharma to Host Second Quarter 2015 Financial Results Conference Call and Webcast
08.06.15
Capricor Therapeutics to Hold Second Quarter 2015 Business Update and Financial Results Conference Call on August 13, 2015 at 4:30 p.m. EDT
08.05.15
Kite Pharma to Present at the Canaccord Genuity 35th Annual Growth Conference
08.04.15
Capricor Therapeutics Appoints Deborah Ascheim, M.D. as Chief Medical Officer
07.01.15
Kite Pharma and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs
06.22.15
Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers
06.22.15
Capricor Therapeutics, Inc. (Nasdaq: CAPR) to Ring The Nasdaq Stock Market Closing Bell
06.17.15
Capricor Therapeutics Appoints Houman Hemmati M.D., Ph.D. to Vice President of Medical and Clinical Development for New Therapies
06.16.15
Kite Pharma to Host Investor Day on June 23, 2015
06.15.15
Capricor Therapeutics and CureDuchenne to Host Webinar on June 19, 2015 at 3:00 p.m. ET
06.08.15
Capricor Announces Receipt of FDA Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy
06.04.15
Arno Therapeutics Announces Issuance of First Onapristone Patent
06.03.15
Arno Therapeutics Announces Cooperative Research and Development
06.02.15
Kite Pharma Presents Clinical Biomarker Results in Patients Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy at the 2015 ASCO Annual Meeting
05.29.15
Kite Pharma to Present Clinical Biomarkers From Patients Treated With Anti-CD19 Chimeric Antigen Receptor T Cell Therapy at the 2015 ASCO Annual Meeting
05.28.15
Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
05.26.15
Capricor Therapeutics to Participate in Two Upcoming Investor Conferences in June
05.26.15
Kite Pharma to Present at the Jefferies 2015 Global Healthcare Conference
05.12.15
Kite Pharma to Report First Quarter Financial Results on Friday, May 15, 2015
05.12.15
Capricor Therapeutics Reports First Quarter 2015 Financial & Business Highlights
05.07.15
Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone
05.05.15
Capricor Therapeutics to Hold First Quarter 2015 Business Update and Financial Results Conference Call on May 12, 2015 at 4:30 p.m. EDT
04.30.15
Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
04.29.15
Arno Therapeutics to Present Three Posters Supporting Onapristone Development at ASCO Annual Meeting 2015
04.22.15
Capricor Granted FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
04.21.15
Arno Therapeutics to Present Promising Data from Phase I Trial of Onapristone at AACR Annual Meeting 2015
04.21.15
Kite Pharma Commends Honors Conferred to Drs. Owen Witte and Steven A. Rosenberg at the 2015 American Association for Cancer Research (AACR) Annual Meeting
04.13.15
Arno Therapeutics Announces Three Poster Presentations at Upcoming AACR Annual Meeting 2015
04.10.15
Kite Pharma to Present at the 2015 Jefferies Immuno-Oncology Summit in Boston
04.08.15
Capricor Completes Enrollment of Initial Phase of DYNAMIC Clinical Trial of Cardiosphere-Derived Cell Therapy for Treatment of Advanced Heart Failure
04.06.15
Kite Pharma Announces Publication in Science of Cancer Immunotherapy Articles Authored by Lead Collaborators at the National Cancer Institute and the Netherlands Cancer Institute
03.31.15
Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure
03.31.15
Arno Therapeutics Reports Fourth Quarter 2014 Financial and Business Update
03.26.15
Kite Pharma Reports Full-Year and Fourth Quarter 2014 Financial Results
03.25.15
Kite Pharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 26th, 2015
03.24.15
New Data Supporting Arno Therapeutics’ HDAC inhibitor AR-42 Published in The Journal of Urology
03.23.15
Capricor Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25, 2015 in New York
03.18.15
Capricor Therapeutics Reports Fourth Quarter and Full Year 2014 Financial & Business Highlights
03.17.15
Kite Pharma Strengthens Its T Cell Receptor (TCR) Cancer Gene Therapy Platform Through Acquisition of T-Cell Factory B.V. (TCF(TM))
03.12.15
Capricor Therapeutics to Hold Fourth Quarter 2014 Business Update Conference Call on March 18, 2015 at 4:30 p.m. EDT
03.10.15
Capricor Therapeutics to Present at the 27th Annual ROTH Conference
03.06.15
Kite Pharma to Present at the 2015 Barclays Global Healthcare Conference
03.05.15
Capricor Announces Enrollment of its Phase II Clinical Trial for Cenderitide to Treat Heart Failure
03.02.15
Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next Generation of Cancer Immunotherapy Products for Solid Tumors
02.23.15
Kite Pharma to Present at the Cowen and Company 35th Annual Health Care Conference
02.19.15
Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products
02.03.15
Kite Pharma Expands and Strengthens Leadership Team
02.02.15
Kite Pharma to Present at the 17th Annual BIO CEO & Investor Conference
01.22.15
Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy
01.19.15
Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process
01.12.15
Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure
01.12.15
Capricor Therapeutics Announces $10 Million Private Placement of Common Stock
01.09.15
Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations
01.08.15
Arno Therapeutics to Present at 11th Annual Noble Equity Conference
01.08.15
Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law
01.07.15
Kite Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference
01.07.15
Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers
01.06.15
Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy
01.05.15
Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies
12.22.14
Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma
12.16.14
Kite Pharma Added to the NASDAQ Biotechnology Index
12.10.14
Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors
12.10.14
Kite Pharma Announces Pricing of Follow-On Offering
12.09.14
Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014
12.04.14
Arno Therapeutics Appoints Alexander Zukiwski, M.D. to Board of Directors –
12.02.14
Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray’s 26th Annual Healthcare Conference
11.26.14
Kite Pharma Files Registration Statement for Proposed Follow-On Offering
11.24.14
Arno Therapeutics to Present at LD Micro Conference 2014
11.18.14
Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy
11.18.14
Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
11.18.14
Kite Pharma Announces Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
11.17.14
Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Investigational Cancer Immunotherapy
11.14.14
Arno Therapeutics Reports Third Quarter 2014 Financial and Business Update
11.14.14
Kite Pharma Reports Third Quarter 2014 Results
11.12.14
Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights
11.07.14
Capricor Therapeutics to Hold Duchenne Muscular Dystrophy Data Presentation Call on November 18, 2014 at 9:30 a.m. ET
11.05.14
Kite Pharma to Participate in Three Upcoming Investor Conferences in November 2014
10.31.14
Capricor Therapeutics to Hold Third Quarter 2014 Business Update Conference Call on November 12, 2014 at 4:30 p.m. ET
10.29.14
Arno Therapeutics’ Executive Selected to Present at 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference
10.27.14
Arno Therapeutics Advances Phase I Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors to Expansion Stage
10.23.14
Arno Therapeutics to Present Encouraging Data from Ongoing Phase I/II Trial Evaluating Onapristone in CRPC at 21st Annual PCF Scientific Retreat
10.14.14
Capricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides From Medtronic, Inc.
10.13.14
Kite Pharma Announces Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells
10.09.14
Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
10.06.14
Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)
10.03.14
Kite Pharma to Participate in Gene Therapy Panel at the BIO Investor Forum
09.30.14
Arno Therapeutics to Present at the 13th Annual BIO Investor Forum
09.18.14
Capricor Presents Safety and Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial at TCT 2014
09.18.14
Arno Therapeutics’ Executive Selected to Chair World CDx Boston 2014
09.16.14
Kite Pharma to Present at the 21st Annual NewsMakers in the Biotech Industry Investment Conference on Friday, September 26
09.08.14
Arno Therapeutics to Present at Upcoming Investor Conferences
08.26.14
Kite Pharma to Present at the Citi 9th Annual Biotech Conference on Wednesday, September 3
08.25.14
Kite Pharma Announces Patients With Aggressive Non-Hodgkin’s Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI)
08.14.14
Arno Therapeutics Reports Second Quarter 2014 Financial and Business Update
08.14.14
Kite Pharma Reports Second Quarter 2014 Results
08.13.14
Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights
08.04.14
Capricor Therapeutics to Hold Second Quarter 2014 Business Update Conference Call on August 13, 2014 at 4:30 p.m. Eastern Time
07.18.14
Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief Operating Officer
07.16.14
Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway
06.23.14
Kite Pharma Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
06.23.14
Capricor Therapeutics to Present at the First Regenerative Medicine Forum at BIO International Convention
06.20.14
Kite Pharma Announces Pricing of Initial Public Offering
06.19.14
Capricor Therapeutics Speaks at Panel on Regulation of Stem Cell-Derived Therapeutic Products at DIA 2014 50th Annual Meeting
05.29.14
Arno Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
05.28.14
Capricor Therapeutics to Present on Exosomes as a Basis for Innovative Platform Technology at 11th International Symposium on Stem Cell Therapy and Cardiovascular Innovations
05.15.14
Capricor Therapeutics Reports First Quarter 2014 Business Highlights
05.15.14
Arno Therapeutics Reports First Quarter 2014 Financial and Business Update
05.14.14
Capricor Therapeutics to Hold First Quarter 2014 Business Update Conference Call on May 15, 2014 at 4:30 p.m. Eastern Time
05.14.14
Arno Therapeutics to Outline Two Phase I Studies Evaluating Onapristone in Men’s and Women’s Cancers at 2014 ASCO Annual Meeting
05.06.14
Capricor Therapeutics Enters Into Exclusive License With Cedars-Sinai Medical Center for Exosome-Related IP Portfolio
05.05.14
Arno Therapeutics Announces Clinical Abstracts Accepted at 2014 ASCO Annual Meeting
04.14.14
Kite Pharma Expands Leadership Team and Announces Senior Management Promotions
04.11.14
Kite Pharma Expands Company’s Board of Directors with the Appointment of Jonathan M. Peacock
04.07.14
Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistant Prostate Cancer
04.02.14
Kite Pharma Announces the Appointment of Arie Belldegrun, M.D., as President and Chief Executive Officer
04.01.14
Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones
03.31.14
Kite Pharma Announces FDA Orphan Drug Designation for Anti-CD19 T Cell Cancer Immunotherapy Product
03.28.14
Capricor Therapeutics to Present ALLSTAR Phase I Trial Data at ACC Annual Meeting 2014
03.26.14
Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014
03.24.14
Arno Therapeutics Board of Directors Appoints Randy Thurman as Vice Chairman
03.10.14
Capricor Therapeutics to Present at Two Upcoming Investor Conferences
03.05.14
Arno Therapeutics to Present at 26th Annual ROTH Conference
03.04.14
Arno Therapeutics Granted Exclusive License for Oncology Diagnostic Technique by University of Minnesota
02.27.14
Arno Therapeutics Appoints Lawrence A. Kenyon Chief Financial Officer
01.21.14
Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors
01.17.14
Kite Pharma Appoints Rizwana F. Sproule, Ph.D., as Vice President, Regulatory Affairs
01.13.14
Arno Therapeutics Expands Management Team with Additions of Two Scientific Leaders
01.09.14
NeoStem’s Subsidiary, Progenitor Cell Therapy (PCT), to Provide Process Development and Manufacturing Services to Kite Pharma
01.09.14
Arno Therapeutics to Present at Biotech Showcase 2014
01.08.14
Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer
01.07.14
Arno Therapeutics Selects Leica Biosystems to Develop Companion Diagnostic for Targeted Oncology Therapy Onapristone
01.06.14
Capricor Therapeutics and Janssen Biotech, Inc. Enter Into Collaboration Agreement and Exclusive License Option
12.20.13
Capricor Therapeutics Announces Ticker Symbol Change to CAPR
12.17.13
Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
12.14.13
Arno Therapeutics to Present Data on Two Potential Predictive Biomarkers at the San Antonio Breast Cancer Symposium 2013
12.07.13
Kite Pharma’s Lead Program with the National Cancer Institute (NCI) Demonstrates Positive Results in Patients with Aggressive Non-Hodgkin’s Lymphoma
12.07.13
Kite Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference
12.07.13
New studies demonstrate that modified T cells are effective in treating blood-borne cancers
11.21.13
Capricor and Nile Therapeutics Complete Merger to Form Capricor Therapeutics, Inc.
11.18.13
Arno Therapeutics Adds Steven Rubin, EVP of OPKO Health, Inc., as Board Observer
09.28.13
Arno Therapeutics to Present Data Validating Target Biomarker at European Cancer Congress 2013
09.09.13
Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors
08.08.13
Kite Pharma Appoints Leading Cancer Immunotherapy Experts to its Scientific Advisory Board
07.08.13
Capricor and Nile Therapeutics Announce Merger Agreement
06.21.13
Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
06.03.13
Arno Therapeutics to Collaborate With Veridex on Development of Diagnostic Test
05.30.13
Kite Pharma Appoints Keith Nolop, M.D. Chief Medical Officer
05.15.13
Kite Pharma Completes $35 Million Series A Preferred Stock Financing
05.15.13
Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
05.10.13
Arno Therapeutics to Collaborate with Clarient for Development of Diagnostic Test
04.08.13
Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to Onapristone
03.19.13
Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel
03.07.13
Capricor, Inc. Appoints Anthony Davies, Ph.D., Chief Technology Officer
01.31.13
Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors
12.19.12
Arno Therapeutics Completes $14.9 Million Financing To Advance Lead Clinical Compounds
12.05.12
Arno Therapeutics Reports Findings of New Diagnostic Technique the Potential to Identify Patients with Cancer Who May Respond to Treatment with Onapristone
11.27.12
Arno Therapeutics Completes $12.7 Million Financing
11.09.12
Arno Therapeutics Reports Progress in Development of Clinical Biomarkers to Support Treatment of Breast Cancer with Onapristone
10.16.12
Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products
10.01.12
US launch of Forfivo XL (bupropion HCl extended-release tablets)
06.07.12
Arno Therapeutics Announces Additional Orphan-Drug Designations for AR-42 in Europe
05.11.12
Arno Therapeutics Announces Orphan-Drug Designation for AR-42 in Europe
02.21.12
Arno Therapeutics Receives Two Orphan-Drug Designations for AR-42 in Treatment of Central-Nervous-System Tumors
02.14.12
Arno Therapeutics Announces Exclusive Licensing Agreement with Invivis Pharmaceuticals to Develop Cancer Drug
01.01.12
US launch of Fluoxetine Tablets, 60 mg
07.19.11
Veterans of J&J, Pfizer, and Medimmune Seek to Transform Arno into Oncology Powerhouse
07.11.11
Kite Pharma Appoints Adrian Bot, M.D., Ph.D., as Chief Scientific Officer
06.27.11
Arno Therapeutics Names Alexander Zukiwski, M.D., Vice President and Chief Medical Officer
06.23.11
Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue
05.26.11
Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
05.03.11
Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
04.28.11
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
03.31.11
Nile Therapeutics Receives Fast Track Designation for Cenderitide for Post-Acute Indication
03.09.11
Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors
02.28.11
Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
02.28.11
Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
09.20.10
Kite Pharma Appoints Dr. Gloria Lee Chief Medical Officer
09.16.10
Aya Jakobovits, Ph.D., Named President and CEO of Kite Pharma, Inc.
09.13.10
Arno Therapeutics, Inc. Raises $15 Million in Private Placement To Advance Clinical Development of Oncology Compounds
06.17.10
Arno Therapeutics Announces Dosing of First Patient in a Phase I/IIa Study of AR-42, a broad spectrum histone and non-histone deacetylation inhibitor (pan-DAC)
12.17.09
Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 in Patients with Glioblastoma Multiforme (GBM)
12.15.09
Arno Therapeutics Announces Poster Presentation at ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity of AR-42
09.01.09
Acquired US license and supply agreement for EDG003
08.27.09
Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway
07.23.09
Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 (formerly DB-67) in Patients with Myelodysplastic Syndrome
05.27.09
Arno Therapeutics Announces Three Poster Presentations at ASCO Annual Meeting
05.11.09
FDA Accepts Arno Therapeutics’ IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
05.04.09
Arno Therapeutics to Deregister its Common Stock under the Exchange Act
03.31.09
Arno Therapeutics Reports 2008 Year-End Financial Results
03.17.09
FDA Accepts IND for Arno Therapeutics’ Pan-DAC/Akt Inhibitor, AR-42
11.14.08
Arno Therapeutics Announces Third Quarter 2008 Financial Results
11.03.08
Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10.30.08
Arno Therapeutics Appoints William F. Hamilton to Board of Directors
09.03.08
Arno Therapeutics Announces Appointment of Roger G. Berlin, MD, as Chief Executive Officer and Director
09.03.08
Acquired US patent rights for EDG005
08.18.08
Arno Therapeutics Announces Second Quarter 2008 Financial Results
08.14.08
Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
08.14.08
Capricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development
07.16.08
Arno Therapeutics Announces New Ticker Symbol
07.15.08
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock
06.05.08
BioWorld Today – Arno Gets $18M Plus Market Access in Reverse Merger
06.05.08
Arno Therapeutics Completes $30.7 Million Financing, Recapitalization and 1-for-8 Reverse Stock Split
06.04.08
Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger
06.04.08
Arno Therapeutics Data Supports Further Evaluation of Onapristone in Prostate Cancer
01.28.08
Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
01.28.08
Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance – Biotrial to Serve as Contract Research Organization for Paris-Based Trial